Genmab A/S

Coloplast exists to make life easier for people with intimate healthcare needs - conditions that are deeply personal and often difficult to discuss. Founded in 1954 by nurse Elise Sørensen, who created the world's first adhesive ostomy bag to help her sister Thora live without fear of leakage, Coloplast has grown from a single act of empathy into a global medical device leader serving over 2 million people across more than 100 countries. The company's intimate healthcare portfolio spans Ostomy Care, Continence Care, Wound & Tissue Repair, Interventional Urology, Bowel Care, and Voice & Respiratory Care - products designed to help people manage private health conditions with dignity and confidence. Headquartered in Humlebæk, Denmark, with approximately 16,500 employees across 41 countries, Coloplast remains guided by the founding spirit of closeness, passion, and respect. The company's user-centric innovation process starts by listening deeply to understand real challenges, then responding with solutions that genuinely improve quality of life. Beyond products, Coloplast offers Coloplast Care - a comprehensive support program providing practical guidance and emotional education for users - and Coloplast Professional, which equips healthcare providers with specialized resources and training. This dual focus on product innovation and human support reflects Coloplast's fundamental belief that empathy and responsibility drive meaningful progress in intimate healthcare.

In 1878, a young entrepreneur named Henri Goldstuck recognized a critical need in the bustling port of Rouen, France. As grain shipments flowed through one of the country's largest ports, he saw that buyers and sellers needed an independent, trustworthy way to verify quality. So he founded a grain inspection house that would eventually transform into the world's most trusted name in testing, inspection, and certification. From those humble beginnings on the docks of 1870s Rouen, SGS evolved into a global powerhouse with over 99,500 professionals operating across 2,500 laboratories and business facilities in 115 countries. After moving headquarters to Geneva, Switzerland in 1915 and adopting the name Société Générale de Surveillance, the company expanded beyond grain inspection to serve virtually every industry. Today, SGS combines Swiss precision with deep expertise across oil and gas, manufacturing, healthcare, technology, and sustainability sectors, guided by a simple promise that has endured for over 145 years: when you need to be sure.

DSV builds the economic infrastructure for global trade. Founded in 1976 in Denmark, DSV has evolved from a small group of independent hauliers into one of the world's largest transport and logistics companies. Today, DSV provides and manages supply chain solutions for thousands of companies across more than 90 countries, serving customers ranging from small family-run businesses to large global corporations. The company operates through three core divisions: Air & Sea, Road, and Contract Logistics, offering comprehensive services including air freight, sea freight, road transport, rail freight, warehousing, and customized logistics solutions. With a global network of over 3,000 offices and logistics facilities and approximately 150,000 employees, DSV keeps supply chains flowing efficiently worldwide. The company's growth strategy combines strategic acquisitions - including Panalpina in 2019, Agility's Global Integrated Logistics in 2021, and Schenker in 2025 - with organic expansion to strengthen its position as a global top-three logistics provider.

Amgen is a worldwide pioneer in biotechnology, harnessing the best of biology and technology to fight the world's toughest diseases. Founded in 1980 in Thousand Oaks, California, Amgen has grown from a pioneering biotech startup with just a handful of employees into one of the world's leading independent biotechnology companies. For over 45 years, Amgen has been committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. The company's reach extends to millions of patients globally, transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. As an American multinational biopharmaceutical company, Amgen focuses on four key therapeutic areas: cardiovascular metabolic, bone health, inflammation, and oncology. The company's robust pipeline leverages state-of-the-art science and molecular engineering, pursuing transformative medicines with large effects. Amgen's commitment to patients is matched by its investment in its workforce, offering comprehensive benefits that support work-life balance, health, and career growth. With operations spanning the globe and a mission to make people's lives easier, fuller, and longer, Amgen continues to push the boundaries of what's possible in biotechnology and medicine.

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Founded in 2008, we engineer life-changing immunology solutions through our antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate discovery. Our flagship product, VYVGART (efgartigimod alfa), is a first-in-class neonatal Fc receptor blocker approved for the treatment of generalized myasthenia gravis, with potential to treat patients across dozens of severe autoimmune conditions. The name argenx originates from the ancient myth of the Argonauts - one of the first stories recognizing the power of the team over individual heroes. This philosophy of co-creation drives everything we do. We believe the resilience and hope of patients gives us purpose, empowering us to work with urgency because we know they are waiting. Our cultural pillars - Innovation, Co-creation, Excellence, Humility, and Empowerment - guide our business relationships and collaborations both within and beyond our walls as we strive to achieve the unthinkable together.

At Galderma, we've been dedicated to skin health for over 40 years. Founded in 1981, we're the only truly scaled pure-play dermatology company, working exclusively with the human body's largest organ. Our 7,000+ employees across approximately 90 countries deliver science-based solutions across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. We achieved 4.410 billion USD in net sales in 2024, reflecting our leadership position in the dermatology market. We believe everyone's skin story is unique. That's why we've built a portfolio of premium brands that meet diverse individual needs. From our roots as a joint venture between Nestlé and L'Oréal, to becoming the world's largest independent global dermatology company in 2019, and our IPO on the SIX Swiss Exchange in 2024, we've remained focused on advancing dermatology through innovation, scientific rigor, and partnership with healthcare professionals. Our unique Integrated Dermatology Strategy drives our growth as we continue developing breakthrough treatments and training programs through our Global Aesthetic Injector Network.